New hope: testing targeted drug before surgery for aggressive ovarian cancer
NCT ID NCT03943173
Summary
This early study is testing whether a drug called olaparib can help shrink tumors before surgery in people newly diagnosed with advanced ovarian cancer that has a BRCA gene mutation. The trial involves about 15 participants who will take olaparib pills for up to two months before receiving standard surgery and chemotherapy. The main goal is to see if this approach is safe and feasible, and to check if the drug reduces the size of the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.